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(sPLA2) enzymes, mostly com-
prising sPLA2-IIA, sPLA2-III,
sPLA2-V, and sPLA2-X, hydro-
lyze phospholipids from the cell
membrane surface and lipopro-
teins, producingpro-inﬂammatory
lysophospholipids and eicosanoids
(1). This activity may also modify
low-density lipoprotein cholesterol
(LDL-C) particles in the circula-
tion increasing the binding of
LDL-C onto blood vessel wall
proteoglycans, promoting foam
cell formation and the develop-
ment of atherosclerosis (2).
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n Health Scientist Fellowship G0802432: tosPLA2 enzymes (2) and itsmass can be quantiﬁed speciﬁcally in
plasma by enzyme-linked immunosorbent assay (3). In
contrast, the assay for sPLA2 enzyme activity does not distin-
guish between the secretory isoenzymes IIA, III, V, and X (2).
Observational studies have indicated that higher circulating
sPLA2-IIA mass and sPLA2 enzyme activity are associated
with an increased risk of incident and recurrent MVE
(comprising cardiovascular death, myocardial infarction [MI],
and stroke) (3–6), with the evidence being more compelling
in primary prevention (4) than in patients with ACS (7). This
suggests that sPLA2 isoenzymes, in particular IIA, may
represent a novel therapeutic target for cardiovascular disease
prevention. This hypothesis is supported by studies in mouse
models that show over-expression of sPLA2-IIA associates
with increased atherosclerotic lesion size (8).
Despite these encouraging ﬁndings, mechanistic studies in
animals may not faithfully model the disease process in
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sPLA2-IIA mass or sPLA2 enzyme activity may be a conse-
quence not a cause of atherosclerosis or reﬂect an association
with causal risk factors. An evaluation of sPLA2 as a thera-
peutic target is timely to help put into context the recent
announcement that a phase III randomized trial (VISTA-16
[Vascular Inﬂammation Suppression to Treat Acute Coro-
nary Syndrome for 16Weeks] trial) (10) of varespladib, aﬁrst-
in-class sPLA2 inhibitor (9) for major vascular event (MVE)
prevention in patients with acute coronary syndrome (ACS),
was stopped prematurely for lack of efﬁcacy (11). Varespladib
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1970ARTerial disease] study), and 1 nested case-control study of
coronary artery restenosis in patients with ACS undergoing
percutaneous coronary intervention (GENDER [GENetic
Determinants of Restenosis] study). These additional studies
did not contribute toward the analyses set in general pop-
ulation or ACS studies, and were analyzed and reported
separately (Online Appendix). Finally, tissue samples from 1
cohort of patients undergoing aortic valve surgery (ASAP
[Advanced Study of Aortic Pathology]) were used to investi-
gate the association of single-nucleotide polymorphisms
(SNPs) in PLA2G2A with mRNA expression in liver,
mammary artery, aorta, and heart with an external data source
comprising 206 transplant donor liver samples used for repli-
cation (14). Approval from relevant ethical committees was
obtained for collaborating studies. All analyses, unless other-
wise stated, were performed using Stata 12.1 (StataCorp,
College Station, Texas).
Measurement of sPLA2-IIA mass and sPLA2 enzyme
activity. sPLA2-IIA mass and sPLA2 enzyme activity were
measured in 7 and 6 of the collaborating studies, respectively
(Online Table 2). Assay methods are reported in Online
Table 3. Owing to the time of blood sampling being
greater than 1 month after the acute coronary event, samples
for the KAROLA (Langzeiterfolge der KARdiOLogischen
Anschlussheilbehandlung) study were not included in the
analysis. The distributions of both sPLA2-IIA mass and
sPLA2 enzyme activity were skewed, hence the traits were
natural log(e) transformed prior to analysis.
Observational analysis. We investigated correlations between
log sPLA2-IIA mass and log sPLA2 enzyme activity in
studies that measured both traits (Online Appendix, Online
Fig. 2). To investigate the association between circulating
sPLA2-IIA mass and sPLA2 enzyme activity with incident
major vascular events in general populations, we used the
European Prospective Investigation of Cancer (EPIC)-Nor-
folk study and to investigate the association with recurrent
events in patients with ACS, we used 4 ACS cohorts (FAST-
MI [French Registry of Acute ST-Elevation or Non–ST-
elevation Myocardial Infarction], GRACE [Global Registry
of Acute Coronary Events]-France, GRACE-Scotland, and
MIRACL [Myocardial Ischemia Reduction with Acute
Cholesterol Lowering] trial). For EPIC-Norfolk, the outcome
was a composite of fatal and nonfatal MI, whereas for the 4
ACS cohorts, it was a composite of all-cause mortality or MI.
First, in the EPIC-Norfolk study we evaluated the cross-
sectional correlates of sPLA2-IIA and sPLA2 enzyme
activity with established and emerging risk factors using linear
or logistic regression as appropriate. Second, we evaluated the
shape of the association between sPLA2-IIAmass and sPLA2
enzyme activity with MI in the general population study, and
with MI/all-cause mortality in the ACS cohorts. Third, we
estimated the magnitude of the association per 1 log unit
lower sPLA2-IIA mass and sPLA2 enzyme activity with MI
or MI/all-cause mortality after statistical adjustment for
potential confounders using logistic regression. Finally, we
explored the independent effect of log sPLA2-IIA mass andlog sPLA2 enzyme activity withMI orMI/all-cause mortality
by ﬁtting a logistic regression model that included both log
sPLA2-IIA mass, and log sPLA2 enzyme activity in addition
to potential confounders. The summary estimates were
pooled across studies using ﬁxed-effects meta-analysis. For
full details of the observational analyses, please see the Online
Appendix.
Genetic analysis. All studies apart from the MIRACL trial
contributed toward the genetic analysis (Online Table 2).
Genotype coding was arranged to be directionally consistent
with the effect of varespladib on sPLA2-IIA mass and sPLA2
enzyme activity. Traits that were nonnormally distributed
(sPLA2-IIA mass, sPLA2 enzyme activity, C-reactive protein,
triglycerides, and interleukin-6) were log(e) transformed,
and differences between genotype groups were reported as
a percentage difference.
Selection of the genetic instrument and evaluation of its
speciﬁcity and effect size. SNP SELECTION. Six tagging
SNPs (15) that captured >90% of genetic variation in
PLA2G2A in Europeans were evaluated in 3 studies (EPIC-
Norfolk, GRACE-France, and UDACS [University College
LondonDiabetes andCardiovascular Study]). The rs11573156
variant that showed the lowest p value with sPLA2-IIA mass
and sPLA2 enzyme activity (Online Fig. 3) was chosen for
Mendelian randomization analysis. Rs11573156 was directly
genotyped in all studies except 2 that imputed it and 1 that used
a proxy SNP. Genotype frequencies were consistent across
studies (Online Fig. 4) and did not deviate from Hardy-
Weinberg equilibrium (at p < 0.001) (Online Table 4).
SPECIFICITY OF GENETIC INSTRUMENT FOR PLA2G2A. Affyme-
trix GeneChip Human Exon 1.0 ST expression arrays were
used to quantify mRNA expression in the ASAP study, in
which participants were genotyped using Illumina Human
610W-Quad Beadarray (including 101 SNPs in the region
200 kb upstream and downstream from the PLA2G2A
locus). Please see the Online Appendix for further details of
estimation of genotype association with mRNA expression.
STRENGTH OF GENETIC INSTRUMENT (RS11573156 C>G) ON
SPLA2. We estimated the per C allele association between
PLA2G2A rs11573156 and sPLA2 measures, as well as the
proportion of variance (R2) of these measures explained by
the rs11573156 variant.
ASSOCIATION BETWEEN GENETIC INSTRUMENT AND PUTATIVE
AND ESTABLISHED CARDIOVASCULAR RISK FACTORS. Twenty
studies of individuals in which blood sampling occurred
prior to the cardiovascular event were used to test the
association of PLA2G2A rs11573156 (per C allele) with
cardiovascular risk factors within each study using linear
regression. Results were pooled using ﬁxed (default) and
random effects meta-analysis.
CARDIOVASCULAR OUTCOMES EXAMINED. For the general
population studies, MVE were separated into prevalent
and incident, whereas for ACS cohorts, all events after
recruitment were included and labeled as recurrent.
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1971Prevalent MVE were a composite of nonfatal MI and
nonfatal stroke, and incident MVE were a composite of
fatal/nonfatal MI and fatal/nonfatal stroke. For ACS
cohorts, recurrent MVE were a composite of nonfatal MI,
nonfatal stroke, and all-cause mortality. Individual compo-
nents of MVE were also reported separately. See the Online
Appendix for outcomes deﬁnitions per study and Online
Table 5 for study contribution to the composite outcome.
ASSOCIATION BETWEEN GENETIC INSTRUMENT AND MVE. We
conducted 2 genetic approaches: ﬁrst, a genetic association
analysis of the PLA2G2A rs11573156 variant with MVE,
and; second, an instrumental variable analysis that quantiﬁed
a causal effect per 1 log unit lower sPLA2-IIA mass and
sPLA2 enzyme activity on MVE, under the assumptions of
instrumental variable analysis (16). A total of 26 studies
contributed to these 2 approaches, comprising 17 in general
populations and 9 studies in patients with ACS.
For the genetic association approach, we estimated the
within-study odds ratio (OR) per C allele of PLA2G2A
rs11573156 with MVE using logistic regression and the
results were pooled using ﬁxed (default) and random-effects
meta-analysis and used I2 to measure heterogeneity. All
meta-analyses were stratiﬁed by clinical setting (general
population or patients with ACS).
For the instrumental variable analysis, we ﬁrst applied the
pooled estimate of the gene variant on log sPLA2-IIAmass and
log sPLA2 enzyme activity to each study, including studies that
did not have measures of sPLA2-IIA mass or sPLA2 enzyme
activity (17). An instrumental variable estimate was then
generated (taking into account the uncertainty inboth the gene-
sPLA2 and gene-outcome associations) (18) for each study.
The study-speciﬁc instrumental variable estimates were pooled
using ﬁxed-effects meta-analysis. Full details of the method-
ology are provided in the Online Appendix. We compared the
instrumental variable estimates to the expected estimates based
on the observational association between sPLA2-IIA mass,
sPLA2 enzyme activity, and cardiovascular events.
Treatment trials of varespladib. In order to contextualize
the effect of the genetic instrument with the sPLA2 inhibitor
(varespladib), we conducted a systematic review of RCTs
(following PRISMA guidance) (19) to evaluate the effects of
varespladib on sPLA2-IIA mass and other cardiovascular
traits. To investigate the dose response between varespladib
and sPLA2-IIA mass, we conducted a meta-regression
analysis (for details, see the Online Appendix).
Results
Observational analysis of sPLA2-IIA mass and sPLA2
enzyme activity. Lower levels of sPLA2-IIA mass and lower
levels of sPLA2 enzyme activity each were associated with
a reduced risk of cardiovascular events in the general population
with an OR for fatal/nonfatal MI of 0.67 (95% conﬁdence
interval [CI]: 0.59 to 0.75) and 0.30 (95%CI: 0.22 to 0.41) per
1 log unit lower sPLA2-IIA mass and sPLA2 enzyme activity,
respectively, after adjustment for age and sex (Fig. 1). Forstudies set in ACS, the corresponding summary ORs for all-
cause mortality or MI were 0.93 (95% CI: 0.84 to 1.04) and
0.82 (95% CI: 0.69 to 0.98), respectively (Fig. 1). The log-
linear model provided the best ﬁt (p  0.1 for a quadratic
model in all comparisons) (Online Table 6), indicating
a constant proportional decrease in the relative odds per 1 log
unit lower sPLA2-IIA mass or sPLA2 enzyme activity.
sPLA2-IIA mass and sPLA2 enzyme activity associated
with several established and emerging cardiovascular risk
factors in the general population (Online Tables 7 and 8). In
general, adjustment for cardiovascular risk factors diminished
the association between sPLA2-IIAmass and sPLA2 enzyme
activity with incident MI in the general population, though
the association persisted following multivariate adjustment
(Fig. 1). Interestingly, both associations (sPLA2-IIA mass
and sPLA2 enzyme activity with MI) remained after adjust-
ment for one another. For ACS cohorts, only sPLA2 enzyme
activity was associated with recurrent events (Fig. 1).
Selection and validation of the genetic instrument for
sPLA2-IIA. rs11573156 C>G showed the lowest p value
with sPLA2-IIA mass (p ¼ 5.49  10–180) and sPLA2
enzyme activity (p ¼ 3.29  10–5) and was prioritized for
analysis in the remaining studies (Online Fig. 3).
To evaluate the speciﬁcity of the rs11573156 variant for
sPLA2-IIA, we analyzed the association of SNPs in
PLA2G2A with mRNA expression of 3 different sPLA2
isoenzymes, encoded by distinct genes (PLA2G2A for
sPLA2-IIA and PLA2G5 for sPLA2-V in close proximity on
chromosome 1, and PLA2G10 for sPLA2-X on chromo-
some 10). PLA2G2A was mainly expressed in the liver, aortic
adventitia and heart (Online Fig. 5). The SNP showing
strongest association with PLA2G2A mRNA expression in
liver was rs10732279A>G (p ¼ 8.71  10–19) (Fig. 2A), in
strong linkage disequilibrium with rs11573156 (R2 ¼ 0.91
in Europeans, HapMap release 21) and explained 31%
of the variance of PLA2G2A mRNA. These ﬁndings
were replicated in an external data source comprising 206
transplant donor liver samples (p ¼ 4.76  10–8) (14).
rs10732279 showed no association with either PLA2G5 or
PLA2G10 mRNA expression conﬁrming the speciﬁcity of
the genetic instrument for sPLA2-IIA (Figs. 2B and 2C).
Association of rs11573156 with sPLA2-IIA mass and
sPLA2 enzyme activity. In 3 studies of 1,400 individuals
with ACS and 2 general population studies of 3,533 indi-
viduals, an allele dose-dependent association was observed
between rs11573156 and sPLA2-IIA mass and sPLA2
enzyme activity (Fig. 3). For each additional C allele of
rs11573156, sPLA2-IIA mass was lower by 38% (95% CI:
36% to 40%) in studies of general populations and 44% (95%
CI: 37% to 50%) in studies of ACS patients, compared with
individuals homozygous for the G allele. The proportion of
variance of sPLA2-IIA mass explained by rs11573156 in
general population and ACS studies was 21% (95% CI: 18%
to 23%) and 6% (95% CI: 3% to 9%), respectively.
In contrast, the effect of the rs11573156 C allele on sPLA2
enzyme activity was smaller and varied considerably by study
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Figure 1
Association of a 1 Log Unit Lower sPLA2-IIA Mass or sPLA2 Enzyme Activity With Fatal/Nonfatal Myocardial Infarction in
General Population Studies and All-Cause Mortality/Myocardial Infarction in Acute Coronary Syndrome Studies
The general population study was EPIC-Norfolk and the 4 acute coronary syndrome cohorts were FAST-MI (French Registry of Acute ST-Elevation or Non–ST-elevation Myocardial
Infarction), GRACE (Global Registry of Acute Coronary Events)-France, GRACE-Scotland, and MIRACL (Myocardial Ischemia Reduction with Acute Cholesterol Lowering). In Model
1, only age and gender were introduced as covariates. We then additionally adjusted for covariates (blood pressure [BP], body mass index [BMI], type 2 diabetes [T2D]) that
could confound the association between secretory phospholipase A2 (sPLA2) and coronary heart disease (CHD; Model 2). Because lipids may mediate the association between
sPLA2-IIA and CHD, we did not include lipids in Model 2, but included them in Model 3 (only available in the general population cohort). Finally, to investigate whether there was
an independent association between sPLA2-IIA mass (orange), sPLA2 enzyme activity (blue), and CHD, we additionally included sPLA2 enzyme activity where sPLA2-IIA mass was
the explanatory variable (and vice-versa; Model 4). CI ¼ conﬁdence interval; HDL-C¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; OR ¼ odds
ratio; TG ¼ triglycerides.
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1972setting, with a 3% reduction (95% CI: 1% to 5%) in studies of
general populations and 23% reduction (95% CI: 19% to
27%) for studies of ACS patients. The proportion of variance
of sPLA2 enzyme activity explained by rs11573156 was 0.5%
(95% CI: 0.0% to 1.0%) and 3% (95% CI: 1% to 5%) in the
general population and ACS cohorts, respectively.
We identiﬁed no major associations between rs11573156
and blood pressure, lipid fractions, inﬂammation markers,
or carotid intima-media thickness (Online Tables 9 to 11).
Comparison of pharmacological modiﬁcation of sPLA2
in randomized clinical trials and carriage of the
PLA2G2A variant in populations. We identiﬁed 4
randomized clinical trials (RCTs) of the sPLA2 inhibitor
varespladib in a total of 1,300 individuals (Online Fig. 6,Online Table 12) (9,20–22). A meta-regression suggested
varespladib treatment produced a dose-dependent reduction in
sPLA2-IIA mass (p for meta-regression ¼ 0.06) (Online
Fig. 7). The most frequently studied dose of varespladib (500
mg/day) reduced sPLA2-IIA mass by 78% (95% CI: 62% to
94%). The effect of varespladib on sPLA2 enzyme activity was
not reported in RCTs because activity was reported to be
beneath the lower limit of quantiﬁcation of the assay (20–22).
Association between rs11573156 and MVE. In a meta-
analysis across 13 population studies (8,021 incident events
in 56,359 individuals), there was no association between the C
allele of rs11573156 and incident MVE (OR: 1.02; 95% CI:
0.98 to 1.06), nor with any of the individual components
(Fig. 4, Online Fig. 8). Similarly, in 12 studies with 7,513
Figure 2 Association of SNPs in the PLA2G2A Region With mRNA Expression
Manhattan plots of single-nucleotide polymorphisms (SNPs) in the PLA2G2A region and association with mRNA expression of (A) PLA2G2A, (B) PLA2G5, and (C) PLA2G10,
color-coded by tissue type. The p values for the association between rs10732279 and mRNA expression of PLA2G5 or PLA2G10 were 0.04 and 0.88, respectively.
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1973prevalent events in 55,523 individuals, there was no association
between the rs11573156 C allele with prevalent MVE
(OR: 0.99; 95%CI: 0.95 to 1.03), or with any of the individual(3/781,NA) (3/398,0%) (3/64,0%) (3/1243,0%)
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Meta-Analysis Pooled Estimates of the Association Betwee
and sPLA2 Enzyme Activity
The analysis is separated by study setting into general populations (EPIC [European Pros
and Cardiovascular Study]; blue) and acute coronary syndrome (FAST-MI [French Registry
Registry of Acute Coronary Events]-France, GRACE-Scotland; red). The percentage estimate
to obtain the relative difference, which was converted to a percentage by subtracting 1 from
because there were too few studies (<3 studies) to synthesize an I2 estimate, or the valu
phospholipase A2.The 3 genotype groups for the rs11573156 SNP are: 1) GG ¼ reference
sPLA2-lowering C-allele.components (Fig. 4, Online Fig. 9). For the 9 ACS studies
with 2,520 recurrent events in 15,768 patients, there was also
no association between the C allele of rs11573156 and(3/892,NA) (3/440,80%) (3/68,64%) (3/1400,82%)
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of Acute ST-Elevation or Non–ST-elevation Myocardial Infarction], GRACE [Global
was obtained by back-transforming the PLA2G2A rs11573156 log sPLA2 association
the relative difference and multiplying the fraction by 100. NA ¼ not applicable either
e could not be calculated for the reference genotype group (GG). sPLA2 ¼ secretory
group; 2) CG: 1 copy of the sPLA2-lowering (common) C-allele; 3) CC: 2 copies of the
Figure 4
Meta-Analysis Pooled Estimates of the Association Between PLA2G2A rs11573156 and MVE
(Including Individual Components) Stratiﬁed by Clinical Setting Into General Population and ACS Patients
Each plot represents the PLA2G2A rs11573156 per C allele odds ratio, with genotype grouping arranged to mimic the effects of pharmacological lowering of secretory
phospholipase A2 (sPLA2)-IIA (i.e., if lowering of sPLA2-IIA mass were to reduce risk of cardiovascular events, the odds ratio in the plot should be <1). Major vascular events
(MVE) comprise fatal/nonfatal MI or stroke in general population studies and fatal/nonfatal MI or stroke or all-cause mortality in ACS studies. CI ¼ conﬁdence interval. Fatal
myocardial infarction (MI)/stroke included all-cause mortality for some acute coronary syndrome (ACS) studies (see Online Table 5 for further details).
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1974recurrent MVE (OR: 0.96; 95% CI: 0.90 to 1.03) (Fig. 4,
Online Fig. 10). Similar ﬁndings were obtained using
a random-effects model for meta-analysis (Online Table 13).
Extreme genotype comparison. Individuals homozygous
for the rs11573156 C allele had a 57% to 62% lower sPLA2-
IIA mass compared with those homozygous for the G allele
(Fig. 3), which was similar in magnitude to the 78%
reduction seen with 500 mg/day varespladib dose used in
VISTA-16. Using this genotype comparison, a null effect
was again observed for MVE in all clinical settings: incident
(5,175 cases; OR: 0.99; 95% CI: 0.89 to 1.10), prevalent
(3,545 cases; OR: 1.00; 95% CI: 0.88 to 1.13), and recurrent
(1,626 cases; OR 0.89; 95% CI: 0.74 to 1.06).
Instrumental variable analysis of sPLA2 on MVE. For
the general population studies, instrumental variable analysis
showed a null effect between sPLA2-IIA mass and incident
MVE (OR per 1 log unit lower sPLA2-IIA mass: 1.04; 95%
CI: 0.96 to 1.13) that was in contrast to the expected
association based on observational analysis (OR: 0.69; 95%
CI: 0.61 to 0.79). Similarly, for sPLA2 enzyme activity,
observational studies showed an OR of 0.50 (95% CI: 0.35
to 0.71), yet null associations were obtained for the instru-
mental variable estimates for sPLA2 enzyme activity and
incident MVE (OR: 1.87; 95% CI: 0.47 to 7.49), although
the CIs were wide due to the weak effect of the rs11573156
variant on sPLA2 enzyme activity in the general population.
For the ACS studies, the instrumental variable estimate
for sPLA2-IIA mass and recurrent MVE was also null (ORper 1 log unit lower sPLA2-IIA mass: 0.93; 95% CI: 0.83 to
1.05) and consistent with the observational estimate (OR:
0.92; 95% CI: 0.81 to 1.03). For sPLA2 enzyme activity, no
association was identiﬁed for the instrumental variable
estimate with MVE (OR: 0.86, 95% CI: 0.66 to 1.12),
which was similar to the observational estimate (OR: 0.77,
95% CI: 0.64 to 0.93) (Fig. 5).
Discussion
We used a genetic approach to judge the causal role of
sPLA2-IIA on MVE and, by extension, to evaluate if
inhibition of sPLA2-IIA represents a valid therapeutic tar-
get for cardiovascular prevention. We identiﬁed a SNP in
PLA2G2A (rs11573156) that had a large and speciﬁc effect
on circulating sPLA2-IIA mass and a small-to-modest effect
on sPLA2 enzyme activity, but found no association between
rs11573156 and incident, prevalent or recurrent MVE. This
study provides evidence that the observational association
between sPLA2-IIA mass and MVE is likely due to residual
confounding or reverse causality.
Our Mendelian randomization analysis used a single
genetic instrument that had a remarkable effect on sPLA2-IIA
mass, explaining between 6% and 21% of its variance,
a value several times higher than that observed for all
genome wide association studies hits on blood pressure (1%
for 29 SNPs combined) (23) and similar to that for LDL-C
(w12% for 49 SNPs combined) (24). The strength of our
Figure 5
Observational and Instrumental Variable Estimates Per 1 Log Unit Lower sPLA2-IIA Mass and sPLA2 Enzyme Activity With
Major Vascular Events
The observational analyses were adjusted for age, sex, BMI, BP, T2D, LDL-C, HDL-C, and TG in general population cohorts (corresponding to Model 3 in Fig. 1) and for age, sex,
BMI, and BP in ACS cohorts (corresponding to Model 2 in Fig. 1). Abbreviations as in Figure 1.
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1975genetic instrument together with the large sample size
analyzed strongly support the instrumental variable estimates
that indicate a null effect of sPLA2-IIA mass with cardio-
vascular events.
The key SNP in our study (rs11573156) had a smaller
impact on sPLA2 enzyme activity than sPLA2-IIA mass, in
particular for general population studies. Because sPLA2
enzyme activity is a composite of several sPLA2 isoenzymes
(2), it is not surprising that a PLA2G2A SNP (speciﬁc for
sPLA2-IIA) explained a smaller proportion of variance of
sPLA2 enzyme activity compared with sPLA2-IIA mass.
While this manuscript was being prepared, a phase III
RCT of varespladib (VISTA-16) (10) was halted for lack of
efﬁcacy (11). VISTA-16 was to enroll up to 6,500 patients
with ACS and randomize them to 500 mg/day varespladib
or placebo for 16 weeks with a primary combined endpoint
of cardiovascular death, nonfatal MI, nonfatal stroke, or
documented unstable angina. We hypothesize that the nullﬁndings from our Mendelian randomization analysis may
provide an eventual explanation for the lack of efﬁcacy of
varespladib in VISTA-16.
We did not ﬁnd an association between lower sPLA2-IIA
mass and lower rates of recurrentMVE in ACS patients, unlike
earlier reports (10). With CIs that span ORs from 0.81 to 1.03,
we cannot rule out a false negative ﬁnding due to a limited
number of events. Alternatively, initial studies often over-
estimate the effect of a biomarker on a health outcome, and as
more evidence accrues, themagnitude of the effectmay diminish
and in some cases disappears, known as the “winner’s curse.”
Study limitations. First, we did not have data from
a common set of participants with all 3 key variables: sPLA2
measures, genetic information, and cardiovascular events.
This is a common scenario with large-scale meta-analyses of
Mendelian randomization studies that include novel bio-
markers (25), but the instrumental variable approach helps
overcome this problem. Second, given the impact of the SNP
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1976on sPLA2 enzyme activity wasmoremodest than its effect on
sPLA2-IIA mass, our genetic analyses do not exclude
a possible causal role of other isoforms such as sPLA2-III,
-V, and -X in cardiovascular disease. However, our genetic
data do provide clear evidence against a causal role of sPLA2-
IIA mass in incident MVE in the general population. With
regard to an ACS population, our analysis includes 2,520
recurrentMVE in patients withACS,which is 6-fold greater
than the 385 primary events that VISTA-16 intended to
accrue (10). Furthermore, comparing individuals homozy-
gous for the rs11573156C allele to those homozygous for the
G allele resulted in a reduction in sPLA2-IIAmass similar to
the effect of varespladib 500 mg/day and also showed no
association with MVE.
Conclusions
Our large-scale Mendelian randomization analysis sug-
gests that sPLA2-IIA is unlikely to be a valid therapeutic
target for prevention of cardiovascular events. The
concordance of our genetic ﬁndings with the lack of
efﬁcacy of the phase III varespladib trial supports the
wider use of this type of genetic approach earlier in drug
development to prioritize which drug targets to take
through to RCTs.
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APPENDIX
For an expanded methods and results sections and supplemental ﬁgures
and tables, please see the online version of this article.
